FOURTH QUARTER AND PRELIMINARY FINANCIAL RESULTS FOR 2023 FOR MEDISTIM ASA

Sales ended at MNOK 135.6, 4.4 % below our all-time high Q4 last year (MNOK 141.8). Full year sales revenue is a new record at MNOK 526.4 (MNOK 491.9), up 7.0 %.

Currency neutral sales of own products was down 17.4 % for the quarter and down 5.1 % for the year.

Recurring sales remain high at 69 % (67 %) for the year, underscoring the sustained momentum in utilization among our customers.

Operating profit (EBIT) for the quarter ended at MNOK 22.3 giving a 16.4 % EBIT margin (MNOK 36.5, a 25.7 % margin). For the full year, EBIT ended at MNOK 131.4, giving a 25.0 % margin (MNOK 141.3, a 28.7 % margin).

In 2023, our largest market, USA, experienced a decrease in capital sales, but rising probe sales indicate a growing utilization.

Solid cash position of MNOK 153.9 at year end and no long-term interest-bearing debt.

With a firm belief in further growth, the Board proposes to the General Assembly a dividend of NOK 4.50 (NOK 4.50) per share